{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["39 Suppl 1"],"submitter":["Gerdes S"],"pubmed_abstract":["<h4>Background</h4>G-EPOSS is a prospective, non-interventional, German multicentre study of patients with moderate-to-severe plaque psoriasis receiving guselkumab, a therapeutic monoclonal antibody targeting interleukin-23, in a real-world setting.<h4>Objectives</h4>The objective of the study was to evaluate the effectiveness and safety of guselkumab, including its impact on skin, health-related quality of life (HRQoL), sexuality, and perceived stigmatization.<h4>Methods</h4>Patients (≥18 years old) received guselkumab per routine clinical practice. The primary endpoint was the proportion of patients achieving absolute Psoriasis Area and Severity Index (PASI) ≤ 3 at Week (W)28. Secondary endpoint assessments over 28 weeks included the Nail Psoriasis Severity Index (NAPSI), anogenital Phys"],"journal":["Journal of the European Academy of Dermatology and Venereology : JEADV"],"pagination":["15-26"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11862875"],"repository":["biostudies-literature"],"pubmed_title":["Effectiveness, safety and impact of guselkumab on sexuality and perceived stigmatization in patients with psoriasis in routine clinical practice: Week 28 results from the prospective German multicentre G-EPOSS study."],"pmcid":["PMC11862875"],"pubmed_authors":["Joks G","Ostendorf R","Mortazawi D","Behrens J","Trenkler N","Makuc J","Tabori S","Gerdes S","Suß A","Taut F","Schadeck T","Scharfenberger L","Jacobsen S"],"additional_accession":[]},"is_claimable":false,"name":"Effectiveness, safety and impact of guselkumab on sexuality and perceived stigmatization in patients with psoriasis in routine clinical practice: Week 28 results from the prospective German multicentre G-EPOSS study.","description":"<h4>Background</h4>G-EPOSS is a prospective, non-interventional, German multicentre study of patients with moderate-to-severe plaque psoriasis receiving guselkumab, a therapeutic monoclonal antibody targeting interleukin-23, in a real-world setting.<h4>Objectives</h4>The objective of the study was to evaluate the effectiveness and safety of guselkumab, including its impact on skin, health-related quality of life (HRQoL), sexuality, and perceived stigmatization.<h4>Methods</h4>Patients (≥18 years old) received guselkumab per routine clinical practice. The primary endpoint was the proportion of patients achieving absolute Psoriasis Area and Severity Index (PASI) ≤ 3 at Week (W)28. Secondary endpoint assessments over 28 weeks included the Nail Psoriasis Severity Index (NAPSI), anogenital Phys","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2025-04-03T23:14:13.04Z","creation":"2025-04-03T23:14:13.04Z"},"accession":"S-EPMC11862875","cross_references":{"pubmed":["38602225"],"doi":["10.1111/jdv.19927"]}}